***SUPPORTING STATEMENT:*** *PART A*

**Drug Overdose Response Investigation (DORI) Data Collection**

**OMB# 0920-1054**

November 15, 2017

Point of Contact:

Christine L. Mattson

Department of Health and Human Services (DHHS)

Centers for Disease Control and Prevention (CDC)

National Center for Injury Prevention and Control (NCIPC)

Division of Unintentional Injury Prevention

4770 Buford Highway NE MS F-62

Atlanta, GA 30341-3724

Phone #: 404.639.8572

Email: ggi8@cdc.gov

**Table of Contents**

A. Summary Table

Justification

1. Circumstances Making the Collection of Information Necessary

2. Purpose and Use of Information Collection

3. Use of Improved Information Technology and Burden Reduction

4. Efforts to Identify Duplication and Use of Similar Information

5. Impact on Small Businesses or Other Small Entities

6. Consequences of Collecting the Information Less Frequently

7. Special Circumstances Relating to the Guidelines of

5 CFR 1320.5(d)2

8. Comments in Response to the Federal Register Notice and Efforts to Consult Outside the Agency

9. Explanation of Any Payment or Gift to Respondents

10. Protection of the Privacy and Confidentiality of Information Provided by Respondents

11. Institutional Review Board (IRB) and Justification for Sensitive Questions

12. Estimates of Annualized Burden Hours and Costs

13. Estimates of Other Total Annual Cost Burden to Respondents or Record Keepers

14. Annualized Cost to the Government

15. Explanation for Program Changes or Adjustments

16. Plans for Tabulation and Publication and Project Time Schedule

17. Reason(s) Display of OMB Expiration Date is Inappropriate

18. Exceptions to Certification for Paperwork Reduction Act Submissions

**Attachments**

A. Authorizing Legislation

B. Published 60-day notice

C. Public Comments

D. Request Protocol Template

E. Burden Memo

F. Protocol Request - Fentanyl-heroin overdose deaths OH

G. Final Burden Memo – Fentanyl-heroin overdose deaths OH

H. Data Collection Instruments – Fentanyl-heroin overdose deaths OH

I1-I5. Summary of Previous Epi-Aid DORIs and Sample Data Collection Instruments

J. NCIPC Determination of human subjects

**Drug Overdose Response Investigations (DORI) Data Collections**

1. **A. Justification**

Summary Table

* Goal of the study: The goal of Drug Overdose Response Investigations (DORI) is to collect data in response to an urgent request from a state or local health authority to inform responses to control a local drug overdose epidemic. When a data collection meets criteria for review and approval under the Paperwork Reduction Act, approval will be sought for the data collection through this generic Information Collection Request (ICR). The National Center for Injury Prevention and Control (NCIPC) anticipates that information will need to be collected to (a) understand sudden increases in drug use and misuse associated with fatal and nonfatal overdoses (e.g., collect data on type of drug, number of cases, time of increasing trend, morbidity and mortality), (b) understand the drivers and risk factors associated with those trends (e.g., collect data on circumstances surrounding overdose), and (c) identify the groups most affected.
* Intended use of the resulting data: The resulting data about drug use and misuse and associated fatal and nonfatal overdoses will be used to identify actions that can be taken to control a local drug overdose epidemic.
* Methods to be used to collect: The jurisdiction requesting assistance determines the specific data collection needs that CDC can fulfill. CDC staff may provide technical assistance with developing questionnaires and a data analysis plan or may be deployed to the field to assist in operations of the investigation. Examples of data collection modes that could be employed during DORIs include: archival record abstraction and review, face-to-face interview, telephone interview, web-based questionnaire, or self-administered questionnaire. Multiple data collection modes may be employed in a single investigation. Data collection instruments and methods will be rapidly created and implemented to meet the unique needs of the situation and the agency requesting assistance, often immediately before deployment. Revisions will often be required when investigators are in the field.
* The subpopulation to be studied: Likely respondents include: public health authorities, law enforcement authorities, medical examiners, individuals who suffer from nonfatal overdose, families and friends of individuals who succumb to drug overdose, members of the general public, and individuals who are at higher risk for overdose (e.g., those suffering from addiction), health care providers/pharmacists; dispensers of prescription medication, Emergency Medical Services personnel, representatives of community organizations (e.g., substance use service providers)
* How data will be analyzed: Data analysis will depend on the method of collection and content, but it is anticipated that most DORIs will involve computing basic descriptive statistics to characterize the population experiencing overdoses (e.g. the number and rate of fatal and/or non-fatal overdose cases, along with demographic characteristics); the creation an epidemic curve to graphically display the numbers of incident fatal or non-fatal overdose cases, plotted over time; and potentially a bivariate exploration of risk and protective factors associated with overdose between cases and controls.

1. **Circumstances Making the Collection of Information Necessary**

The Centers for Disease Control and Prevention (CDC) National Center for Injury Prevention and Control (NCIPC) seeks OMB approval for an extension of this generic clearance (OMB control number 0920–1054, Expiration 03/31/218) for a 3-year period, to conduct investigations of drug use and misuse and associated fatal and nonfatal overdose (hereafter referred to as “Drug Overdose Response Investigations (DORIs)”). In this context, drug overdose refers to overdose from prescription drugs (with a special interest in opioid analgesics such as oxycodone or methadone; benzodiazepines such as alprazolam) and/or illicit drugs (e.g., heroin, illicitly manufactured fentanyl, cocaine).

Given the rapidly changing landscape of the drug overdose epidemic, including the declaration of a national public health emergency and the fact that seven states have declared state emergencies (Arizona, Arkansas, Florida, Maryland, Massachusetts, Missouri, Virginia) the need to use this generic mechanism is expected to increase. As of September 2017, CDC now funds enhanced surveillance of fatal and nonfatal opioid overdoses in 32 states and the District of Columbia. These enhanced surveillance efforts will likely increase the potential of identifying outbreaks that may require the use of DORI. While states continue to develop their capacity to respond to increases in drug overdoses, some still require substantial technical assistance. Because the epidemiology of drug overdoses varies in terms of which populations are affected and which drugs are fueling the overdoses, it is important that CDC preserve the ability to rapidly provide a catered response to protect the public’s health.

Background

DORIs are data collections conducted in response to urgent requests from state and local health authorities. Traditionally, these data collections are conducted in the context of an Epi-Aid; however, DORIs may also be conducted in response to a direct request from state or local health departments to NCIPC. The Epi-Aid mechanism is enacted to support a field response, and provides CDC with the agility to respond rapidly to serious and urgent public health crises. Epi-Aids are used to provide epidemiological information, as quickly as possible, to inform the selection of interventions to lessen or prevent illness, injury, or death. Epi-Aids may or may not include data collection. The goal of DORIs is to collect data to inform responses that can be taken to control a local drug overdose epidemic. When a DORI data collection is conducted in response to an urgent request from a state or local health authority, and the data collection meets criteria for review and approval under the Paperwork Reduction Act, approval will be sought for the data collection through this ICR. Based on previous experience, NCIPC anticipates that information will need to be collected to (a) understand sudden increases in drug use and misuse associated with fatal and nonfatal overdoses (e.g., collect data on type of drug, number of cases, time of increasing trend, morbidity and mortality), (b) understand the drivers and risk factors associated with those trends (e.g., collect data on circumstances surrounding overdose), and (c) identify the groups most affected (e.g., collect data on emergency department admissions or decedents). It is expected that investigations will often require collection of information from 10 or more respondents (or 10 or more organizations that serve as respondents), with the collection of information on the same topic and use of similarly structured questions.

In 2015, CDC received OMB approval (OMB control number 0920–1054) for a new OMB generic clearance for a 3-year period to collect information to response to conducted in response to urgent data collection requests from states. The DORI ICR was previously determined to assist CDC in responding to state requests given that the generic ICR that covers Emergency Epidemic Investigations (EEI) may not be an appropriate fit for data collections in response to drug overdose. The potential lack of fit is due to requirements of the EEI Generic ICR (that is, undetermined agent, source, mode of transition, or risk factors in urgent public health emergencies). The legal justification for conducting emergency requests from states about drug overdose can be found in the Public Health Service Act (42 USC Sec. 301 [241] (a) (Authorizing Legislation, **Attachment A**).

Generic clearance is requested to ensure that timely information is collected during a DORI, which allows NCIPC to maintain critical mission function by working with state and local health authorities to protect the public’s health. During an unanticipated rise in a nonfatal or fatal drug overdose where the substances responsible for the health event need to be identified, drivers and risk factors are undetermined, and/or subgroups at risk need to be identified, immediate action by CDC is necessary to minimize or prevent public harm. CDC must have the ability to rapidly deploy data collection tools to understand the scope of the problem and determine appropriate action. CDC seeks an extension for this Generic ICR to ensure that the Agency is poised to mobilize quickly and mitigate harm to the public when urgent epidemiologic data collection support is requested by our state and local health authority partners, and that data collection meets criteria for review under the Paperwork Reduction Act.

Over the last three years, this generic clearance was used to support one request from the Ohio Department of Health soliciting CDC’s assistance with an investigation to identify risk factors for fentanyl-related overdose deaths in the state. Fentanyl, a synthetic, short-acting opioid analgesic, is 50–100 times more potent than morphine and is approved for the management of severe or chronic pain, typically among opioid-tolerant patients. In March 2015, the U.S. Drug Enforcement Administration (DEA) issued a nationwide alert on fentanyl as a threat to health and public safety. Identifying the circumstances and risk factors that contributed to this increase in deaths was critical to implementing prevention strategies to prevent additional deaths. Therefore, the Ohio Department of Health requested CDC assistance with an investigation to identify risk factors for fentanyl-related overdose deaths in the state. On 10/20/2015 CDC-NCIPC requested and received approval from OMB, through CDC-ICRO, for this GenIC titled “Undetermined risk factors for fentanyl-related overdose deaths- Ohio” (**Attachment F**). At the completion of the investigation, the team submitted the final burden memo (see **Attachment G**) and associated data collection instruments (**Attachment H1 through H6**). NCIPC is taking this opportunity to report to OMB the final documents associated with the mentioned GenIC. In the future, NCIPC will provide the final burden memo and associated data collection instruments, for all the GenIC received under the DORI mechanism, to OMB during the approval request of the generic ICR.

CDC-NCIPC requested OMB approval for a single GenIC during the reporting period. However, this was not based on state need, but rather based on limited CDC staffing resources. Unfortunately, due to inadequate staffing at CDC, NCIPC turned down multiple state requests for assistance (i.e., Nevada, Illinois, West Virginia and Delaware). In light of NCIPC’s enhanced opioid surveillance efforts and expanded staffing, we expect the number of states requesting assistance and our ability to respond to such requests to grow, particularly when we may be asked to participate in multistate investigations.

**2. Purpose and Use of Information Collection**

The purpose of this ICR is to allow for rapid data collection within DORIs that are conducted in response to an urgent request for assistance from state or local health authorities. This renewal seeks the continued ability for data collection that meets requirements for review and approval under the Paperwork Reduction Act. This data collection will allow for the gathering of information about drug use and misuse and associated fatal and nonfatal overdoses to identify actions that can be taken to control a local drug overdose epidemic. To accomplish this objective, data on the conditions surrounding and preceding the onset of the drug overdose events of interest must be collected rapidly. The negative consequence of not performing this data collection is the inability to respond to state technical assistance requests and resulting increase or sustained morbidity and mortality associated with the local drug overdose epidemic.

**Need**. Deaths from drug overdose have been rising steadily over the past two decades and have become the leading cause of injury death in the United States. In 2015, drug overdoses accounted for 52,404 U.S. deaths and 63% involved an opioid. The age-adjusted opioid-involved death rate increased by 15.6%, from 9.0 per 100,000 in 2014 to 10.4 in 2015. This increase was driven largely by increases in deaths involving heroin and synthetic opioids other than methadone. Further, the Drug Enforcement Administration (DEA) found that the number of drug products obtained by law enforcement that tested positive for fentanyl nationally increased by 426% during 2013–2014; and among 27 states, fentanyl seizure increases were strongly correlated with increases in synthetic opioid deaths. In addition, between 2005 and 2014, the rate of opioid-related ED visits increased 99.4%, from 89.1 per 100,000 population in 2005 to 177.7 per 100,000 population in 2014. During the same time period, the rate of opioid-related inpatient stays increased 64.1%, from 136.8 per 100,000 population in 2005 to 224.6 per 100,000 population in 2014.

State and local health authorities are responsible for tracking and controlling local epidemics. However, state and local health authorities often require epidemiologic assistance and support from CDC to assist in data collection so that complex and immediate demands for information can be met. Authorities rely on CDC to respond quickly to their requests for short-term data collection support. NCIPC is uniquely qualified to assist in data collection on drug overdose using DORIs given its expertise in investigating emerging trends in drug overdose, the drivers and risk factors associated with trends, and the groups most affected.

**Circumstances**. This generic clearance was established to address drug overdose

when there is a request from state or local health authorities to investigate alarming and emerging trends in drug overdose that require immediate response, the drivers and risk factors associated with such trends, and the groups most affected. When assistance is requested by a state or local health authority, CDC makes every effort to respond by providing data collection support to inform public health action. Requests for DORIs will typically emerge through the Epi-Aid mechanism.

When the need to collect data from 10 or more entities is indicated, the circumstances that justify an urgent DORI data collection include:

* Increased overdoses (e.g., increase in number of nonfatal or fatal overdoses or accelerating trends)
* Occurrence of a rare or unknown cause of morbidity or mortality related to drug overdose (e.g., inclusion of rare substances, such as in the case of fentanyl-laced heroin, fentanyl analogues, or other new synthetics)
* Opportunity to identify new information, such as risk factors previously unassociated with drug overdose or a change in indicators of death (e.g., reports of changes in breathing function prior to death that could signal the need for intervention)
* Occurrence among a particular population (e.g., children)
* Public or political concern (e.g., state governor declaration of a public health emergency in a given state)

The circumstances that would not justify a DORI include:

* Investigations for the purposes of program evaluation, surveillance, needs assessment, or research conducted primarily to contribute to generalizable knowledge.

**Scope of data collection**. The jurisdiction requesting assistance determines the specific data collection needs that CDC can fulfill. CDC staff may provide technical assistance with developing questionnaires and a data analysis plan. CDC staff may be deployed to the field to assist in some or all of the operations of the investigation. This can include conducting training, determining sampling frames, and collecting data. CDC staff may analyze the data (either locally or from Atlanta) and assist in report writing and presenting the final report to the local jurisdiction. The overarching goal when providing data collection support is to implement immediate prevention and control measures based on the findings from the investigation to minimize adverse health consequences.

The information collected varies by DORI depending on the nature of the event. Based on previous experience, NCIPC anticipates that state requests will result in the need to collect data to (a) understand sudden increases in drug use and misuse associated with fatal and nonfatal overdoses (e.g., collect data on type of drug, number of cases, place and time of increasing trend, morbidity and mortality, medical conditions or symptomology information), (b) understand the drivers and risk factors associated with those trends (e.g., collect data on circumstances surrounding overdose, environmental factors, potential exposures, risk behaviors), and (c) identify the groups most affected (e.g., collect data on emergency department admissions or decedents to determine differences by demographics or location).

In DORIs, draft data collection instruments are developed prior to investigation initiation in the field. However, sufficient information is most often not available to allow for complete development of data collection instruments far in advance. Data collection instruments and methods must be rapidly created and implemented to meet the unique needs of the situation and the agency requesting assistance, often immediately before deployment, with needed revisions identified while investigators are in the field. Specific questions might change or new questions could evolve during the course of the investigation as new information is revealed. The choice of data collection mode may be influenced by what is already known about the problem; the location, size, and characteristics of the affected population; and resources available to local health authorities and the team in the field.

Examples of data collection modes that could be employed during DORIs include:

* archival record abstraction and review
* face-to-face interview
* telephone interview
* web-based questionnaire
* self-administered questionnaire

Multiple data collection modes can be employed in a single investigation. It is anticipated that the most common data collection modes will include record abstraction and in-person interviews.

Respondent type will vary by investigation. Likely respondents include:

* Public health authorities
* Law enforcement authorities
* Medical examiners
* Individuals who suffer from nonfatal overdose
* Families and friends of individuals who succumb to drug overdose
* Members of the general public, and individuals who are at higher risk for overdose (e.g., those suffering from addiction)
* Health care providers/pharmacists; dispensers of prescription medication
* Emergency Medical Services personnel
* Representatives of community organizations (e.g., substance use service providers)

Data could be collected in multiple cities, counties, or even states depending on the size and scope of the epidemic. For example, out of state residents can access health providers and dispensers in another state to inappropriately access prescription drugs; contaminated or high potency drugs could be distributed over a large geographic area causing spikes in overdoses. It is anticipated that there will be no more than 10 DORIs per year.

**3. Use of Improved Information Technology and Burden Reduction**

During DORIs, there often is not sufficient time to develop, test, and launch electronic systems for collection of data. However, DORIs will employ online or electronic submission of responses when feasible. If this mode is utilized, it will be password-protected. To minimize burden, existing data from medical records, for instance, could potentially be used to pre-populate data collection tools.

Data collection protocols are designed to be as unobtrusive as possible, and only the minimal information necessary is collected to reduce burden to the respondent. The specific data collection protocol is tailored to meet the immediate needs of the local health authorities responding to the public health problem.

**4. Efforts to Identify Duplication and Use of Similar Information**

Literature searches and discussions with local health authorities are initially conducted to determine the extent of existing information. If found, previous information is used, whenever appropriate, to contribute to an investigation. However, an emergency situation generally requires the collection of data specific to the particular event as each situation is unique in many aspects (e.g. class of drug, method of drug administration, location, affected populations, risk factors, and environmental factors).

NCIPC has reached out to other Centers within CDC (the National Center for Environmental Health, Division of Environmental Hazards and Health Effects) to determine the type of information collected by those Centers (within Epi-Aids and otherwise) related to prescription drugs to ensure that the collection of information is not duplicative and that other Centers are not collecting similar information. When Epi-Aid or other urgent data collection requests are received from state and local health authorities related to drug overdose, NCIPC reaches out to other Centers conducting work on prescription drugs to ensure that similar information does not already exist to meet the state/local health authorities’ needs. NCIPC has also reached out to the Substance Abuse and Mental Health Services Administration to ensure the proposed data collection is not duplicative of any of their efforts in working with states.

A CDC staff person will continue to serve in the role of DORI Information Collection Request Liaison (ICRL). The ICRL will be responsible for maintaining a data collection instrument library which will include the final data collection instruments administered in DORIs under this ICR. In the event a collection is requested from a CDC program, the ICRL will require the program to determine whether or not the information already exists, and to use data collection instruments (or components of such instruments) that have already been approved in previous DORIs.

**5. Impact on Small Businesses or Other Small Entities**

Every effort is made to minimize the burden on all respondents during the collection of information during drug overdose investigations. Information collected is held to the absolute minimum required to inform immediate effective prevention and control measures to ease impact on small businesses or entities. No small businesses will be involved in this data collection.

**6. Consequences of Collecting the Information Less Frequently**

DORIs involve one-time, rapid data collection efforts related to a specific event. Not collecting this information impedes CDC from responding to state technical assistance requests and identifying effective prevention and control measures that could lead to reduced morbidity and mortality associated with the local drug overdose epidemic.

**7. Special Circumstances Relating to the Guidelines of 5 CFR 1320.5**

Often, data need to be collected within days or weeks of the request made by the state or local agency. Given the need for rapid data collection to minimize threats to public health, respondents are asked to respond to requests for data in fewer than 30 days.

To ensure that data on drug overdoses are collected in a timely manner to identify immediate prevention and control measures that can protect the health of the public, DORIs will adhere to the following timeline and processes:

1. At the request of the state or local health authority and after consultation with our external partners, CDC decides to organize and deploy a team to provide epidemiological assistance to our partners;
2. Through CDC/ICRO, the OMB Desk officer is notified of the DORI immediately via e-mail from CDC, followed by receipt of the GenIC “Request for Drug Overdose Response Investigation.” This GenIC will include the protocol for the investigation (see **Attachment D**, the investigation protocol template). The protocol describes the circumstances, purpose, case definition, study population, variables of interest, respondents, anticipated burden hours, data analysis plan, synthesis of results, and draft data collection instruments.
3. The OMB desk officer responds with comments on the proposed GenIC DORI within 5 business days. If no response is received within 5 business days, the team assumes that the information collection is cleared.
4. While in the field, minor modifications may be needed to data collection instruments or number of respondents based on new information about the drug overdose events or available data sources. If modifications to the protocol are required, the team will provide a copy of revised data collection instruments and protocol to the ICRL. The ICRL will make a determination as to whether the modifications entail a substantial change in scope or burden hours. If a substantial change is needed, the ICRL will work with the investigators to submit a GenIC with the revised data collection instruments to ICRO. ICRO will send the GenIC with the revised data collection instruments to the OMB desk officer for review. The OMB desk officer will respond with approval or comments for revision within 2 business days. If no response is received within 2 business days, the team assumes that the revisions have been accepted.
5. At the completion of the DORI, the investigators submit the final data collection instrument(s) and associated burden to the ICRL using the “burden memo” (see **Attachment E**).
6. CDC maintains a library of data collection instruments that includes all final data collection instruments conducted under this Generic ICR.

**8. Comments in Response to the Federal Register Notice and Efforts to Consult Outside the Agency**

**A. Federal Register Notice**

**A** 60-day Federal Register Notice was published in the Federal Register on July 17, 2017, Vol. 82, No. 135, page 32705 (**Attachment B**). CDC received one substantive comment and nine non-substantive public comments, four anonymous and five with contact information (**Attachment C**). The CDC’s response to the substantive non-substantive comments received is included in Attachment C.

**B. Efforts to Consult Outside the Agency**

The following are the individuals we consulted with to inform the development of this package. There were no major problems that could not be resolved during the consultation.

**Name**: Danice Eaton

**Title**: Senior Research Scientist, Division of Scientific Education and Professional Development, Center for Surveillance, Epidemiology, and Laboratory Services, Office of Public Health Scientific Services, CDC

**Phone Number**: 404.498.6389

**Email**: [DHE0@cdc.gov](mailto:DHE0@cdc.gov)

**Name**: Tony Richardson

**Title**: Public Health Advisor, Office of Scientific Integrity, Office of the Associate Director for Science, Office of the Director, CDC

**Phone Number**: 404.639.4965

**Email**: [LMR7@cdc.gov](mailto:LMR7@cdc.gov)

**Name**: Rob Lyerla

**Title**: CAPT USPHS, Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration

**Phone Number**: 240.276.0548

**Email**: [rob.lyerla@samhsa.gov](mailto:rob.lyerla@samhsa.gov)

**Name**: Sharon Larson

**Title**: Director, Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration

Phone Number: 240.276.1250

**Email**: [Sharon.larson@samhsa.gov](mailto:Sharon.larson@samhsa.gov)

**Name**: Ellen Yard

**Title**: Epidemiologist, Division of Environmental Hazards and Health Effects, National Center for Environmental Health, CDC

Phone Number: 770.488.3406

**Email**: [IGF8@cdc.gov](mailto:IGF8@cdc.gov)

**Name**: Amy Funk Wolkin

**Title**: Epidemiologist, Division of Environmental Hazards and Health Effects, National Center for Environmental Health, CDC

**Phone Number**: 770.488.3402

**Email**: [AJF9@cdc.gov](mailto:AJF9@cdc.gov)

**Name**: Lauren Lewis

**Title**: Branch Chief, Health Studies Branch, Division of Environmental Hazards and Health Effects, National Center for Environmental Health, CDC

**Phone Number**: 770.488.3428

**Email**: LWB6@cdc.gov

**9. Explanation of Any Payment or Gift to Respondents**

Respondents receive no gift or payment for their participation in any information collections.

**10. Protection of the Privacy and Confidentiality of Information Provided by Respondents**

This submission has been reviewed by the NCIPC’s Information Systems Security Officer, who has determined that the Privacy Act does not apply Data are treated in a secure manner, unless otherwise compelled by law. CDC maintains respondent information by using unique, study identification numbers on all data collection forms. Data may be collected in identifiable form by state partners but de-linked from identifiers and subsequently retrieved by an assigned code rather than name or SSN for CDC use. The lead epidemiologist of the local state investigation will assign and maintain the code and linking information. Personal identifiers and the linkage to the study identification number are maintained separately in locked file cabinets or in encrypted computer files by the state/locality. All personal identifiers are stripped from the data prior to establishing a final data analysis file. Results are published in aggregate form only.

To assist in the review of this ICR, below you will find detailed descriptions of the types of data collection activities that are anticipated for DORIs that would be subject to Paperwork Reduction Act review and approval and would be included within a GenIC. We have also provided examples of past Epi-Aids that presented circumstances that would be similar to justify a DORI covered under this renewal. See **Attachment I1** for a description of past Epi-Aids, in addition to example data collection instruments used in previous Epi-Aid investigations that illustrate sample questions that are consistent with the information collection activities below (**Attachments I2-I5**).

Information collected through DORIs will be shared in aggregate, summary format with state and local health authorities and partners engaged in controlling the local epidemic (e.g., law enforcement, medical examiners, and community organizations). Findings from data analysis will be used by state and local professionals to implement immediate prevention and intervention measures (e.g., task force convening, provision of guidance to Boards of Pharmacy on how to track prescribing and provide feedback to practitioners and implement controls, development of reporting regulations, media outreach efforts).

Information in identifiable form (IIF) may be collected from or about members of the public by states and localities. Examples of IIF categories for which data may be collected include: name, mailing address, e-mail address, phone numbers, and medical information and notes. IIF is only collected when essential to the objective of the investigation. Personal identifiers are not transmitted to CDC; thus, CDC is not collecting IIF. IIF data will not be disclosed unless compelled by law. In no case are IIF included in any report from the investigation.

Individuals are informed that providing information is voluntary. If the respondent participates, consent for participation and sharing of data in aggregate form is assumed.

Potential respondents are informed. Official, written consent is only obtained when it is determined that the data collection involves human subjects research. If research is proposed to accompany the response efforts, all efforts will be taken to ensure that the proposed research complies with all human subjects requirements, including consent requirements. All personal identifiers are stripped from the data prior to delivery of data to CDC or establishing a final data analysis file. Results are only published in aggregate form. A system of records is not being created under the Privacy Act.

Local health authority policies and procedures for data storage and security are followed during each field investigation. Though the type of access control(s) implemented vary according to local policies and procedures, examples include technical controls (e.g., password protection, storage on Virtual Private Network), physical controls (e.g., storage in locked cabinets or rooms), and administrative controls (e.g., daily offsite file back-ups, signed confidentiality agreements by staff who have access to files). Information collection is conducted according to a security plan developed in consultation with the relevant local health authorities. Only staff with approval from the study lead has access to the data. Approvals are granted based on roles or a “need to know basis.”

Personal identifiers are not transmitted to CDC. CDC maintains the integrity of respondent information by using unique, study identification numbers on all data collection forms.

Data are permanent federal records and are maintained in accordance with CDC’s records control schedule (<https://www.archives.gov/records-mgmt/grs.html>). The process for handling security incidents is defined in the system’s Security Plan. Event monitoring and incident response is a shared responsibility between the system’s team and the Office of the Chief Information Security Officer (OCISO). Reports of suspicious security or adverse privacy related events are directed to the component’s Information Systems Security Officer, CDC helpdesk, or to the CDC Incident Response Team. The CDC OCISO reports to the HHS Secure One Communications Center, which reports incidents to US-CERT as appropriate.

**11. Institutional Review Board (IRB) and Justification for Sensitive Questions**

**IRB Approval**

Research is not a primary focus of DORIs, and CDC will not have access to identifiable information; however, if research is proposed to accompany the response efforts, the proposed research will comply with all human subjects requirements. All data sent to CDC will be stripped of identifiers and transmitted in aggregate format. A NCIPC Determination of human subjects review applicability will be included with each submitted GenIC (**Attachment J)**.

**Justification for Sensitive Questions**

Questions that might be considered sensitive (e.g., regarding risk behaviors, attitudes, or medical condition diagnoses) are included only when necessary for the public health response. Before administering data collections, investigators inform respondents (either verbally or in writing) that participation is voluntary, respondents can refuse to answer any questions, and that respondents are not personally identified in any published reports of the study. Participants are also informed the data are being collected in response to drug overdose events, and that the information they provide may help to identify effective prevention and control strategies. Social security numbers are not collected.

**12. Estimates of Annualized Burden Hours and Costs**

CDC projects multiple DORIs annually in response to urgent drug overdose events. The projected average number of respondents is determined upon initial contact by the state or local health authority or requesting organization. CDC estimates that approximately 2000 respondents will participate in DORIs and the average burden per response is 0.5 hours and each respondent is asked to respond once. Therefore, the total estimated annual burden in hours is 1000. While this number may seem high in light of the past infrequent use of DORI, the fact the opioid crisis has been declared a national emergency combined with NCIPC’s enhanced opioid surveillance efforts, the projection is reasonable. The actual number of respondents in each information collection and the number of responses per respondent varies depending on the purpose of each individual GenIC.

Table A-12.1 Estimated Annualized Burden Hours

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Type of Respondents | Form Name | No. of Respondents | No. of Responses per Respondent | Avg. Burden per Response (in hrs.) | Total Burden (in hrs.) |
| Drug Overdose Response Investigation Participants | DORI Data Collection Instruments | 2000 | 1 | 30/60 | 1000 |
|  | Total | | | | 1000 |

There are no anticipated costs to respondents other than time. The U.S. median national hourly wage for all occupations in 2016 based on data from the Bureau of Labor Statistics (available at http://www.bls.gov/oes/current/oes\_nat.htm#00-0000) is $17.81. This wage is assumed for all DORI participants because of the variety of types of participants expected. With a maximum annual respondent burden of 1350 hours, the overall annual cost of respondents’ time for the proposed collection is estimated to be a maximum of $24,044 (1350 burden hours x $17.81).

Estimated Annualized Burden Costs

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Type of Respondents | Form Name | No. of Respondents | No. of Responses per Respondent | Avg. Burden per Response (in hrs.) | Total Burden (in hrs.) | Hourly Wage | Total Respondent Cost |
| Drug Overdose Response Investigation Participants | DORI Data Collection Instruments | 2000 | 1 | 30/60 | 1000 | $17.81 | $17,810 |
| Total $17,810 | | | | | | | |

**13. Estimates of Other Total Annual Cost Burden to Respondents or Record Keepers**

Respondents will incur no capital or maintenance costs.

**14. Annualized Cost to the Government**

There are no equipment or overhead costs. The cost factors considered are related to routine procedures of the investigators in planning investigations; design, preparation, printing, and distribution of questionnaires; and editing, coding, tabulation, analysis, and presentation of the information. The annual cost is estimated based on the U.S. national average hourly wage for epidemiologists in 2016 ($37.37) based on data from the Bureau of Labor Statistics (available at https://www.bls.gov/oes/current/oes\_nat.htm#00-0000). On average, CDC staff and contractors contribute 200 hours per DORI, for a total annualized cost to the Government of $74,740 (see Table A-14.1).

Table A-14.1 Estimated Annualized Cost to the Government

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Staff or Contractor | Average Hours per DORI | Average Hourly Rate | Number of DORIs Annually | Total Annualized Cost |
| Epidemiologist | 200 | $37.37 | 10 | $74,740 |

**15. Explanation for Program Changes or Adjustments**

There are no changes requested for this data collection since the original request is still applicable. As stated, deaths from drug overdose have been rising steadily over the past two decades and have become the leading cause of injury death in the United States. In 2015, drug overdoses accounted for 52,404 U.S. deaths and 63% involved an opioid. The age-adjusted opioid-involved death rate increased by 15.6%, from 9.0 per 100,000 in 2014 to 10.4 in 2015. This increase was driven largely by increases in deaths involving heroin and synthetic opioids other than methadone such as fentanyl. Increases in fentanyl related deaths led to Ohio’s request for CDC assistance. As mentioned, this GenIC titled, “Undetermined risk factors for fentanyl-related overdose deaths- Ohio” was used in order to investigate reasons for the increases seen in Ohio. The results generated from this investigation were disseminated to stakeholders and published an MMWR (<https://www.cdc.gov/mmwr/volumes/65/wr/mm6533a3.htm>). In addition, the Ohio Department of Health published a report on their website (<http://www.odh.ohio.gov/-/media/ODH/ASSETS/Files/health/injury-prevention/2015-Overdose-Data/2015-Ohio-Drug-Overdose-Data-Report-FINAL.pdf>). Despite the limited use of the GenIC in the past, NCIPC anticipates many more state requests and increased staff capacity to respond to such requests in light of the national emergency declaration to respond to the opioid crisis.

**16. Plans for Tabulation and Publication and Project Time Schedule**

The epidemiologic data collected in each DORI provides information necessary for an effective public health response to drug use and misuse and associated fatal and nonfatal overdose. Therefore, collecting data as soon as possible after the onset of the overdose events is critical to the epidemiologic analysis. The duration of the data collection varies by DORI.

|  |  |
| --- | --- |
| **Project Time Schedule** | |
| Activity | Time Schedule |
| Letter received from health agency requesting assistance | Investigation initiation |
| Convening of health scientists, epidemiologists, etc. | Within 1 week after investigation initiation |
| Development of data collection instrument or selection from instrument library | Weeks 1 to 3 after investigation initiation |
| GenIC submission and approval | Week 3 after investigation initiation |
| Deployment into the field | Weeks 4 to 6 after project initiation |
| Data collection in the field | Weeks 4 to 10 after project initiation (staff may be in the field for up to 3 weeks) |
| Data collection from CDC | Weeks 6 to 12 after investigation initiation (all data collected within 3 months) |

For each DORI, the lead investigator is responsible for developing an analysis plan and conducting the data analysis. A preliminary report summarizing the early findings of the investigation is written by the lead investigator and provided to CDC within 14 days of the completion of the investigation. Any publication of data derived from a DORI is subject to review by relevant local health authorities, CDC, or collaborating federal agencies.

CDC may receive requests to release the information (e.g., congressional inquiry, Freedom of Information Act requests). The Agency disseminates the findings when appropriate, strictly following the Agency's "Guidelines for Ensuring the Quality of Information Disseminated to the Public."

**17. Reason(s) Display of OMB Expiration Date is Inappropriate**

The display of the OMB expiration date is not inappropriate.

**18. Exceptions to Certification for Paperwork Reduction Act Submissions**

There are no exceptions to the certification.